The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

نویسندگان

  • Ludwig Kappos
  • Gilles Edan
  • Mark S. Freedman
  • Xavier Montalbán
  • Hans-Peter Hartung
  • Bernhard Hemmer
  • Edward J. Fox
  • Frederik Barkhof
  • Sven Schippling
  • Andrea Schulze
  • Dirk Pleimes
  • Christoph Pohl
  • Rupert Sandbrink
  • Gustavo Suarez
  • Eva-Maria Wicklein
  • S Strasser-Fuchs
  • T Berger
  • K Vass
  • C Sindic
  • B Dubois
  • D Dive
  • V Delvaux
  • J Debruyne
  • L Metz
  • G Rice
  • M Kremenchutzky
  • P Duquette
  • Y Lapierre
  • M Freedman
  • A Traboulsee
  • P O'Connor
  • P Stourac
  • R Talab
  • M Valis
  • O Zapletalova
  • I Kovarova
  • E Medova
  • J Fiedler
  • J Frederiksen
  • B Brochet
  • T Moreau
  • P Vermersch
  • J Pelletier
  • G Edan
  • M Clanet
  • B David
  • P Clavelou
  • C Lebrun-Frenay
  • O Gout
  • M Kallela
  • T Pirttila
  • J Ruutiainen
  • JP Erälinna
  • K Koivisto
  • M Reunanen
  • I Keskinarkus
  • I Elovaara
  • A Villringer
  • H Altenkirch
  • L Bauer
  • M Ghazi
  • C Pohl
  • K Wessel
  • H-P Hartung
  • W Steinke
  • B Kieseier
  • H Kolmel
  • P Oschmann
  • M Berghoff
  • R Diem
  • B Kitze
  • A Dressel
  • F Hoffmann
  • K Baum
  • S Jung
  • H Felicitas Petereit
  • D Reske
  • M Sailer
  • J Kohler
  • B Tackenberg
  • L Klotz
  • R Hohlfeld
  • T Kuempfel
  • K-H Henn
  • A Steinbrecher
  • K Angstwurm
  • H Tumani
  • R Gold
  • P Rieckmann
  • C Kleinschnitz
  • R Komoly
  • G Gacs
  • G Jakab
  • G Panczel
  • T Csepany
  • L Csiba
  • L Vecsei
  • A Miller
  • D Karussis
  • J Chapman
  • A Ghezzi
  • G Comi
  • V Martinelli
  • P Gallo
  • V Cosi
  • R Bergamaschi
  • L Durelli
  • P Cavalla
  • CH Polman
  • F Barkhof
  • B Uitdehaag
  • B Anten
  • R Hupperts
  • L Visser
  • K-M Myhr
  • A Szczudlik
  • K Selmaj
  • Z Stelmasiak
  • H Barosik-Psujek
  • R Podemski
  • Z Maciejek
  • S Wawrzyniak
  • L Cunha
  • S Sega-Jazbec
  • X Montalbán
  • T Arbizu
  • A Saiz Hinarejos
  • J Barcena
  • S Martínez Yélamos
  • R Arroyo
  • O Fernandez
  • G Izquierdo Ayuso
  • B Casanova i Estruch
  • J Lycke
  • L Kappos
  • A de Vera
  • S Wu
  • E-W Radue
  • J Kuhle
  • H Mattle
  • K Beer
  • R Coleman
  • DH Miller
  • J Chataway
  • J O'Riordan
  • S Howell
  • HF McFarland
  • J Kesselring
  • AJ Petkau
  • KV Toyka
چکیده

OBJECTIVE To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment. Eleven years after randomization, patients were reassessed. RESULTS Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible at participating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk of CDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (p = 0.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931 [253, 3,296]; p = 0.0005) and lower overall annualized relapse rate (0.21 vs 0.26; p = 0.0018). Only 25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiple sclerosis. Expanded Disability Status Scale scores remained low and stable, with no difference between treatment arms (median [Q1, Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better Paced Auditory Serial Addition Task-3 total scores (p = 0.0070). Employment rates remained high, and health resource utilization tended to be low in both groups. MRI metrics did not differ between groups. CONCLUSIONS Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in both groups, this supports the value of treatment at CIS. CLINICALTRIALSGOV IDENTIFIER NCT01795872. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The effect of exercise therapy on knee osteoarthritis: a randomized clinical trial

  Background: Knee osteoarthritis (OA) is the most common musculoskeletal disease among old individuals which affects ability for sitting on the chair, standing, walking and climbing stairs. Our objective was to investigate the short and long-term effects of the most simple and the least expensive exercise protocols in combination to conventional conservative therapy for knee OA.   Methods : It...

متن کامل

CLINICAL TRIAL OF TRICLABENDAZOLE ON HUMAN FASCIOLIASIS: LONG TERM FOLLOW UP

Following an outbreak: of human fascioliasis in Gilan province of Iran in 1989, the benzimidazole derivative triclabendazole (TCBZ) was suggested as the drug of choice after finding out that routine drugs were not effective. Two studies were performed: a clinical trial (before/after type) in 1989 and a historical cohort (1989- 1995) to examine the efficacy of the drug. TCBZ was administere...

متن کامل

Evaluating the Effectiveness of Short-term Clinical Guideline to Treat Sexual Addiction Disorder in People With Sexual Addiction: A Clinical Trial

Objectives Sex addiction is one type of behavioral addiction that is characterized by extreme fantasies and hard-to-control sexual behaviors. This disorder causes problems in the lives of affected people and their victims. The treatment is non-pharmacological and psychological, which are time-consuming and expensive. Short-term interventions are one of the ways to help these people. This study ...

متن کامل

Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone

BACKGROUND There are limited long-term randomized controlled trials of growth hormone (GH) supplementation to adult height and few published reports of the health-related quality of life (HRQOL) following treatment. The present follow-up study of young adults from a long-term controlled trial of GH treatment in patients with Turner syndrome (TS) yielded data to examine whether GH supplementatio...

متن کامل

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

The objective of this study was to assess long-term blood pressure control in resistant hypertension patients receiving baroreflex activation therapy (BAT). Following completion of the randomized Rheos Pivotal Trial, patients participated in open-label, nonrandomized follow-up to assess safety and efficacy of BAT. Blood pressure reductions were measured relative to a pre-implant baseline as wel...

متن کامل

Long-term outcomes of lumbar spinal stenosis: eight-year results of the Spine Patient Outcomes Research Trial (SPORT).

STUDY DESIGN Randomized trial with a concurrent observational cohort study. OBJECTIVE To compare 8-year outcomes of surgery with nonoperative care for symptomatic lumbar spinal stenosis. SUMMARY OF BACKGROUND DATA Surgery for spinal stenosis has been shown to be more effective than nonoperative treatment during 4 years, but longer-term data are less clear. METHODS Surgical candidates from...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 87  شماره 

صفحات  -

تاریخ انتشار 2016